Pay in 4 interest-free payments of $9.75 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
PubMed PMID: 10726989
The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling
Marcellin P
InChiKey: WEVYNIUIFUYDGI-UHFFFAOYSA-N
Check for active clinical trials or closed clinical trials using this agent
MI-2 - Menin-MLL Inhibitor. CAS# 1271738-62-5 60033 PubMed PMID: 10726989MI 2, CAS No. 1271738 62 5, is a potent and specific Menin MLL inhibitor with an IC50 ~446 nM. It specifically binds to Menin and inhibits Menins interaction with MLL fusion proteins in cells. It can effectively reverse MLL fusion proteinmediated leukemic transformation by downregulating the expression of target genes downstream of MLL fusion protein oncogenic activity. MI 2 is a new tool for better understanding MLL mediated leukemogenesis and